Evidence map›Paper›PMID 36700398›Full record

ArticleHaematologica2023

Duality of Nrf2 in iron-overload cardiomyopathy.

Enrica Federti, Francesca Vinchi, Iana Iatcenko, Alessandra Ghigo, Alessandro Matte, Serge Cedrick Mbiandjeu Toya, Angela Siciliano, Deborah Chiabrando, Emanuela Tolosano, Steven Zebulon Vance and 6 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Iron Dysregulation in Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Enrica FedertiDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Francesca VinchiIron Research Laboratory, Lindsley Kimball Research Institute, New York Blood Center, New York, NY, USA; Dept. of Pathology and Laboratory Medicine, Weill Cornell Medicine.
Iana IatcenkoDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Alessandra GhigoDepartment Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarrone", University of Torino, Torino.
Alessandro MatteDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Serge Cedrick Mbiandjeu ToyaDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Angela SicilianoDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Deborah ChiabrandoDepartment Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarrone", University of Torino, Torino.
Emanuela TolosanoDepartment Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarrone", University of Torino, Torino.
Steven Zebulon VanceIron Research Laboratory, Lindsley Kimball Research Institute, New York Blood Center, New York, NY.
Veronica RiccardiDepartment of Medicine, University of Verona and AOUI Verona, Verona.
Immacolata AndolfoDepartment of Molecular Medicine and Medical Biotechnologies, Federico II University of Naples; CEINGE - Biotecnologie Avanzate, Naples.
Manuela IezziDepartment of Medicine and Aging Science, "G. d'Annunzio" University of Chieti, Chieti.
Alessia LamolinaraDepartment of Medicine and Aging Science, "G. d'Annunzio" University of Chieti, Chieti.
Achille IolasconDepartment of Molecular Medicine and Medical Biotechnologies, Federico II University of Naples; CEINGE - Biotecnologie Avanzate, Naples.
Lucia De FranceschiDepartment of Medicine, University of Verona and AOUI Verona, Verona. lucia.defranceschi@univr.it.
University of Verona · ITUniversity of Turin · ITCeinge Biotecnologie Avanzate (Italy) · ITUniversity of Chieti-Pescara · ITCornell University · USNew York Blood Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiomyopathy deeply affects quality of life and mortality of patients with b-thalassemia or with transfusion-dependent myelodysplastic syndromes. Recently, a link between Nrf2 activity and iron metabolism has been reported in liver ironoverload murine models. Here, we studied C57B6 mice as healthy control and nuclear erythroid factor-2 knockout (Nrf2-/-) male mice aged 4 and 12 months. Eleven-month-old wild-type and Nrf2-/- mice were fed with either standard diet or a diet containing 2.5% carbonyl-iron (iron overload [IO]) for 4 weeks. We show that Nrf2-/- mice develop an age-dependent cardiomyopathy, characterized by severe oxidation, degradation of SERCA2A and iron accumulation. This was associated with local hepcidin expression and increased serum non-transferrin-bound iron, which promotes maladaptive cardiac remodeling and interstitial fibrosis related to overactivation of the TGF-b pathway. When mice were exposed to IO diet, the absence of Nrf2 was paradoxically protective against further heart iron accumulation. Indeed, the combination of prolonged oxidation and the burst induced by IO diet resulted in activation of the unfolded protein response (UPR) system, which in turn promotes hepcidin expression independently from heart iron accumulation. In the heart of Hbbth3/+ mice, a model of b-thalassemia intermedia, despite the activation of Nrf2 pathway, we found severe protein oxidation, activation of UPR system and cardiac fibrosis independently from heart iron content. We describe the dual role of Nrf2 when aging is combined with IO and its novel interrelation with UPR system to ensure cell survival. We open a new perspective for early and intense treatment of cardiomyopathy in patients with b-thalassemia before the appearance of heart iron accumulation.

Indexed as

CardiomyopathiesIron OverloadThalassemiaAnimalsHepcidinsIronMaleMiceNF-E2-Related Factor 2Quality of LifeHepcidinsIronNfe2l2 protein, mouseNF-E2-Related Factor 2

Identifiers

PMID36700398
PMCPMC10153524
OpenAlexW4318065362

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.